Tvardi Therapeutics Inc 宣布，计划将其候选药物Tti-109的开发重点，拓展至由STAT3信号通路驱动的皮肤病和胃肠道疾病领域。然而，这一战略推进的实施，将取决于公司能否成功获得必要的额外资金。
STAT3作为一种关键的转录因子，在细胞增殖、存活及免疫调节中扮演核心角色。其异常激活与多种炎症性和自身免疫性疾病的病理过程密切相关。Tti-109旨在靶向并抑制STAT3的活性，从而可能为这些难治性疾病提供新的治疗选择。
公司表示，新的开发计划将基于Tti-109已有的临床前数据及其作用机制的科学依据。资金到位后，将启动针对特定适应症的进一步临床前研究，并为后续的临床试验做准备。此举标志着Tvardi在探索其核心资产Tti-109治疗潜力方面，迈出了战略性的一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.